Moreover, since transthoracic echocardiography (TTE) is the key investigation for CHD diagnosis and monitoring, the same guidelines recommend performing a TTE every 6–12 months in any patient with CS and/or a high 5-HIAA level with CHD symptoms and/or an NT-proBNP > 260 pg/mL. Here, NPPB is linked to coronary artery disorder.